Drug Trial Radar · NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
735
Planned (sponsor's estimate)
Start
Aug 8, 2023
Primary completion
Jun 1, 2032
Study completion Jul 1, 2035
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Chronic Lymphocytic
- Small-Cell Lymphoma
- Lymphoma, Small Lymphocytic
- CLL
- SLL
Interventions
NemtabrutinibDrug
5, 20, and 45 tablets
VenetoclaxDrug
10, 50, and 100 mg tablets
RituximabBiological
100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 12 Weeks
- Part 1: Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 28 months
- Part 1: Number of Participants Discontinuing Study Treatment Due to AEsTime frame: Up to approximately 25 months
- Part 2: PFS per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 71 months
Locations
107 sites in 23 countries. Site status is shown where the registry gives one.
Highlands Oncology Group ( Site 5405)
Springdale, Arkansas · Recruiting
MemorialCare Health System - Long Beach Medical Center ( Site 5421)
Long Beach, California · Recruiting
Clermont Oncology Center ( Site 5430)
Clermont, Florida · Recruiting
Memorial Hospital West ( Site 5410)
Pembroke Pines, Florida · Recruiting
Fort Wayne Medical Oncology and Hematology ( Site 5444)
Fort Wayne, Indiana · Recruiting
Center for Cancer and Blood Disorders ( Site 5439)
Bethesda, Maryland · Recruiting
Avera Cancer Institute - Marshall ( Site 5462)
Marshall, Minnesota · Recruiting
Hattiesburg Clinic Hematology/Oncology ( Site 5416)
Hattiesburg, Mississippi · Recruiting
MidAmerica Cancer Care, LLC ( Site 5426)
Kansas City, Missouri · Recruiting
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 5433)
Billings, Montana · Recruiting
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 5434)
Reno, Nevada · Recruiting
Atlantic Health System Morristown Medical Center ( Site 5445)
Morristown, New Jersey · Recruiting
New York Oncology Hematology, P.C. ( Site 5453)
Albany, New York · Recruiting
Oregon Health and Science University ( Site 5425)
Portland, Oregon · Recruiting
Avera Cancer Institute - Aberdeen ( Site 5458)
Aberdeen, South Dakota · Recruiting
Avera Cancer Institute - Mitchell ( Site 5461)
Mitchell, South Dakota · Recruiting
Avera Cancer Institute - Pierre ( Site 5460)
Pierre, South Dakota · Recruiting
Avera Cancer Institute- Research ( Site 5437)
Sioux Falls, South Dakota · Recruiting
Avera Cancer Institute - Yankton ( Site 5459)
Yankton, South Dakota · Recruiting
PatientCare Clinical Research LLC ( Site 5435)
Sugar Land, Texas · Recruiting
University of Virginia Cancer Center ( Site 5402)
Charlottesville, Virginia · Recruiting
Vista Oncology ( Site 5449)
Olympia, Washington · Recruiting
Medical Oncology Associates, PS ( Site 5406)
Spokane, Washington · Recruiting
West Virginia University ( Site 5447)
Morgantown, West Virginia · Recruiting
University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423)
Madison, Wisconsin · Completed
Centro Medico Fleischer ( Site 1006)
Buenos Aires, Argentina · Recruiting
Hospital Aleman-oncohematologic diseases ( Site 1001)
Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming ( Site 1005)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Hematology ( Site 1002)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Sanatorio Parque ( Site 1003)
Rosario, Santa Fe Province, Argentina · Recruiting
Royal Adelaide Hospital ( Site 1104)
Adelaide, South Australia, Australia · Recruiting
Box Hill Hospital ( Site 1106)
Box Hill, Victoria, Australia · Recruiting
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103)
Melbourne, Victoria, Australia · Recruiting
ZAS Cadix ( Site 1203)
Antwerp, Belgium · Recruiting
UZ Leuven-Hematology ( Site 1200)
Leuven, Vlaams-Brabant, Belgium · Recruiting
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308)
São Paulo, Brazil · Active not recruiting
Hospital Paulistano-Americas Oncologia ( Site 1302)
São Paulo, Brazil · Recruiting
Hospital Amaral Carvalho-Centro de Pesquisas ( Site 1304)
Jaú, São Paulo, Brazil · Recruiting
The Moncton Hospital ( Site 1414)
Moncton, New Brunswick, Canada · Recruiting
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.